Daniel Shu, MD

University of Pennsylvania, BA, Classics, 2003

University of California, Berkeley, MA, Classics, 2008

Temple University School of Medicine, MD, 2017

Johns Hopkins Hospital, Internal Medicine Residency, 2020

Johns Hopkins Hospital, Medical Oncology Fellowship, 2024

Dr. Shu is an Assistant Professor at the University of Maryland School of Medicine and a medical oncologist in the University of Maryland Greenebaum Comprehensive Cancer Center. He has clinical expertise in treating cancers of the GI tract, including cancers of the liver, bile duct, gallbladder, pancreas, and colon. His research is focused on advancing the care of patients with cancers through greater understanding of the adaptive immune response to cancer. As a postdoctoral medical oncology fellow, he examined the role of tertiary lymphoid structures in the response to neoadjuvant immunotherapy in patients with liver cancer. He has research expertise in multiomic techniques in human immunology, including bulk and single cell RNA, TCR, and BCR sequencing and imaging mass cytometry.  

Liver cancer, cancer immunology, immune checkpoint blockade, neoadjuvant immunotherapy, tertiary lymphoid structures

Shu DH, Sidiropoulos DN. Maturation of Tertiary Lymphoid Structures. Methods Mol Biol. 2025;2864:43-55. doi: 10.1007/978-1-0716-4184-2_3. Review. PubMed PMID: 39527216.

Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, Howe K, Bendinelli KJ, Kartalia E, Qi H, Mo G, Montagne J, Leatherman JM, Lopez-Vidal TY, Zhu Q, Huff AL, Yuan X, Hernandez A, Coyne EM, Zaidi N, Zabransky DJ, Engle LL, Ogurtsova A, Baretti M, Laheru D, Durham JN, Wang H, Sunshine JC, Johnston RJ, Deutsch JS, Taube JM, Anders RA, Jaffee EM, Fertig EJ, Yarchoan M. Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma. Nat Immunol. 2024 Nov;25(11):2110-2123. doi: 10.1038/s41590-024-01992-w. Epub 2024 Oct 25. PubMed PMID: 39455893.

D'Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, Pai M, Goldin RD, Ward SC, Fiel MI, Shu DH, Su YY, Cortellini A, Baretti M, Anders R, Yarchoan M, Hsu C, Marron TU, Pinato DJ. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024 Nov;25(11):1465-1475. doi: 10.1016/S1470-2045(24)00457-1. Epub 2024 Oct 19. PubMed PMID: 39437804.

Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, Northcott J, Lyle J, Rochestie S, Peters J, Connor JT, Jaffee EM, Csiki I, Weiner DB, Perales-Puchalt A, Sardesai NY. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat Med. 2024 Apr;30(4):1044-1053. doi: 10.1038/s41591-024-02894-y. Epub 2024 Apr 7. PubMed PMID: 38584166; PubMed Central PMCID: PMC11031401.